

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706

Status	RECRUITING
Phase	Phase 2
Sponsor	Hanmi Pharmaceutical Company Limited
Enrollment	18 participants

Key Eligibility Criteria

Inclusion (3)

- Men or women, aged 18 years of age or older with SBS resulting in intestinal failure at the time of signing the informed consent form (ICF) (or country's legal age of majority if the legal age is <18 years)
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
- Diagnosis of SBS with the latest intestinal resection being at least 6 months prior to Screening and considered stable regarding the PN/IV need. No restorative surgery planned in the study period.

Exclusion (3)

- Any history of colon cancer.
- History of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free for at least 5 years
- History of alcohol or drug abuse (within 1 year of screening)

Locations (13 total)

Brigham & Women's Hospital, Boston, Massachusetts, United States
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
UZ Leuven, Leuven, Vlaams Brabant, Belgium
... and 10 more locations